A recombinant vector vaccine encoding the structural poly protein of CHIKV that provides protection in mouse model. (Wang et al., 2011)
j.
Mouse Response
Vaccination Protocol:
Female CD-1 outbred mice (Charles River Laboratory, Raleigh, NC) or female C57BL/6 mice (ARC, Perth, Australia) 6–8 weeks old were vaccinated intraperitoneally (i.p.) once with 1 × 108 infectious units of the CAdVax–CHIK vaccine, or the indicated control CAdVax vaccine in 100 μl of PBS, or 100 μl of PBS. (Wang et al., 2011)
Immune Response:
Consistent IgG responses in all outbred CD-1 CAdVax–CHIK immunised mice were apparent at week 2 post vaccination and responses peaked at week 6, with a mean end point titre of ≈1/75,000. No significant antibody reactivity to the ELISA antigen (a lysate of CAdVax–CHIK infected cells) was observed in sera from outbred CD-1 mice vaccinated once with the control CAdVax vector. C57BL/6 CAdVax–CHIK vaccinated mice showed a mean end point titre of over 1 in 3.5 × 10^6 for anti-CHIKV IgG2c. The mean IgG1 titre after CAdVax–CHIK vaccination was over 1 in 3 × 106, significantly higher than that seen after CHIKV infection. C57BL/6 mice vaccinated with the control CAdVax vector or PBS generated no detectable CHIKV-specific IgG1 or IgG2c responses. (Wang et al., 2011)
The highly attenuated poxvirus vector modified vaccinia virus Ankara (MVA) was used to express the CHIKV C, E3, E2, 6K, and E1 structural genes (termed MVA-CHIKV) (GarcÃa-Arriaza et al., 2014).
Challenge Protocol:
The vaccinated mice were challenged with a high-dose of CHIKV (GarcÃa-Arriaza et al., 2014).
Efficacy:
A single dose of MVA-CHIKV protected all mice after a high-dose challenge with CHIKV (GarcÃa-Arriaza et al., 2014).
IV. References
1. GarcÃa-Arriaza et al., 2014: GarcÃa-Arriaza J, Cepeda V, Hallengärd D, Sorzano CÓ, Kümmerer BM, Liljeström P, Esteban M. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. Journal of virology. 2014; 88(6); 3527-3547. [PubMed: 24403588].
2. Lam et al., 2015: Lam S, Nyo M, Phuektes P, Yew CW, Tan YJ, Chu JJ. A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis. mAbs. 2015; 7(6); 1178-1194. [PubMed: 26305993].
